Recent research published in JAMA Network Open is reshaping how doctors and families think about managing peanut allergies in children. Rather than focusing solely on whether a treatment works, experts are increasingly examining long-term value, treatment burden, and quality of life. A new cost-effectiveness analysis suggests that while active peanut allergy treatments cost more upfront than simply avoiding peanuts, they can provide meaningful long-term benefits that may justify the added expense.
The study evaluated two treatment approaches: standard Oral Immunotherapy (OIT), in which children gradually consume increasing amounts of peanut under medical supervision, and Probiotic and Peanut Oral Immunotherapy (PPOIT), which combines OIT with a probiotic supplement. Over a 10-year period, researchers estimated average total costs of approximately AUD $3,582 (USD $2,511) per patient for OIT and AUD $3,956 (USD $2,774) for PPOIT. By comparison, a no-treatment strategy—focused on peanut avoidance and emergency preparedness—was estimated to cost about AUD $249 (USD $175)per patient, largely due to managing accidental allergic reactions.
Although active treatment was considerably more expensive than avoidance alone, it also produced substantially better outcomes. The model estimated annual remission rates of 35.1% for OIT and 34.1% for PPOIT, compared with just 7.3% for children who received no treatment. As a result, both active therapies were considered highly cost-effective when remission was used as the primary measure of success.
The analysis also examined quality-adjusted life years (QALYs), a common healthcare measure that combines both length and quality of life. While OIT achieved slightly higher remission rates, PPOIT generated greater quality-of-life gains over the 10-year modeling period. Researchers estimated that PPOIT provided 0.096 QALYs compared with 0.055 QALYs for OIT, suggesting that the combination approach may offer additional benefits beyond remission alone.
Researchers noted that PPOIT’s quality-of-life advantage may be related to differences in treatment burden or side effects, including fewer gastrointestinal symptoms reported in previous studies. As a result, PPOIT was considered the most cost-effective option when quality-of-life improvements were prioritized.
Importantly, the study found that neither treatment was clearly superior in every situation. OIT was slightly favored when remission was the primary goal, while PPOIT offered greater value when overall quality of life was emphasized. These findings highlight the importance of tailoring treatment decisions to the priorities and preferences of each child and family.
The researchers also found that treatment pricing played a major role in determining overall value. Small changes in the cost of therapy products had a significant impact on cost-effectiveness calculations, making product pricing one of the most influential factors in the analysis.
Ultimately, the findings suggest that peanut allergy treatment decisions should extend beyond simple clinical outcomes. Families and healthcare providers may need to weigh factors such as remission potential, treatment burden, quality of life, side effects, and cost when selecting the most appropriate approach.
As more treatment options become available, personalized care is likely to become an increasingly important part of peanut allergy management. Rather than searching for a single “best” therapy, clinicians and families can work together to identify the option that best aligns with their goals, preferences, and long-term needs.
